November 15, 1995Circulation
Aspirin in the Treatment of Acute Myocardial Infarction in Elderly Medicare Beneficiaries
Key result
Aspirin use within the first 2 days of hospitalization for acute myocardial infarction in elderly patients was associated with significantly lower 30-day mortality (OR 0.78; 95% CI 0.70-0.89).
Why the study?
Does aspirin reduce 30-day mortality in elderly Medicare beneficiaries hospitalized with acute myocardial infarction?
Population
10,018 Medicare beneficiaries >= 65 years old hospitalized with acute myocardial infarction with no absolute…
Comparison
Aspirin administered within the first 2 days of… vs No aspirin administered within the first 2 days…
Design
Cohort
Follow-up
30-day
Authors
Discussion
Loading...
Member takes
Implication
Supports early aspirin consideration in elderly AMI; leaves open randomized confirmation of mortality benefit.
Study Design
Type
Cohort (n=10,018)
Multicenter
Yes
Structured PICO
Does aspirin reduce 30-day mortality in elderly Medicare beneficiaries hospitalized with acute myocardial infarction?
P
Population
10,018 Medicare beneficiaries >= 65 years old hospitalized with acute myocardial infarction with no absolute contraindications to aspirin.
I
Intervention
Aspirin administered within the first 2 days of hospitalization.
C
Comparator
No aspirin administered within the first 2 days of hospitalization.
O
Outcome
30-day mortality.hard clinical
Main Result
Effect estimate: OR 0.78 (95% CI 0.70-0.89)
In elderly Medicare beneficiaries with acute myocardial infarction, aspirin use within the first 2 days of hospitalization is associated with a 22% lower odds of 30-day mortality, yet remains underutilized in high-risk patients.
Cite This Study
Krumholz et al. (1995) conducted a cohort in Acute myocardial infarction (n=10,018). Aspirin vs. No aspirin within the first 2 days of hospitalization was evaluated on 30-day mortality (OR 0.78, 95% CI 0.70-0.89). Aspirin use within the first 2 days of hospitalization for acute myocardial infarction in elderly patients was associated with significantly lower 30-day mortality (OR 0.78; 95% CI 0.70-0.89).